Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can stem cells rebuild the brain after stroke?

NCT ID NCT04631406

Cure Sponsor: Clarion Cells, Inc. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 13, 2026 · Updated 2 times

Summary

This trial tests whether transplanting neural stem cells directly into the brain can help people who have had a chronic ischemic stroke. The study involves adults aged 18-75 who had a stroke 6 to 60 months prior. Participants receive a single dose of stem cells, and the trial evaluates safety and potential improvements in motor function.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Neural stem cells (NR1) derived from human embryonic stem cells, injected directly into the brain
What this could lead to
If successful, this could lead to a new treatment that repairs brain damage and improves motor function after a stroke.
What could go wrong
This is an early-stage trial with a small number of participants, so safety and effectiveness are not yet proven. There are risks from the surgical procedure and the need for immunosuppression.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 1/2

Runs two stages together: safety and dose first, then whether the treatment works.

Participants

About 27 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2021

Expected to finish

Aug 2029

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 - 75 years * History of ischemic subcortical stroke in the middle cerebral artery and/or lenticulostriate artery 6 to 60 months from time of stroke * Ability of subject to understand and provide written Informed Consent * Willing to take tacrolimus (Prograf) 2 days before and for 2 months after transplant Exclusion Criteria: * Stroke lesion less than 1 cubic centimeter or greater than 100 cubic centimeters measured by MRI * Index stroke is lacunar infarct less than 1 year old * History or presence of any major neurological disease * History of active cancer other than basal or squamous cell skin cancers * History of seizures * Pregnant or breast-feeding

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Ischemic stroke are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

ischemic stroke

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Ischemic stroke

Contacts and locations

Locations

  • Stanford Health Center

    Stanford, California, 94305, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.